Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Endologix Shows How Growth-Hungry Med-Tech Investors Are

Since it seems to be accepted practice now to accuse anyone who doesn't think your stock is a screaming buy today with being "secretly short", let me be very clear from the get-go - I like Endologix (NASDAQ:ELGX) quite a lot as a company, I think the company's technology is innovative, and I see the company as both a share-gainer in endovascular AAA treatment and one of the best growth stories today in med-tech. All of that said, I don't see it as a bargain unless/until a larger med-tech company decides that it must have it as its own.

Solid Technology Leads To Good Products And Good Growth

The history of Endologix is actually pretty convoluted and interesting...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details